Our Expert Network

  1. Scaling RNA Production From The Lab To The Clinic 8/9/2024

    Nutcracker's unique approach to scaling up to clinical manufacturing — which brings unique challenges compared to traditional biologics — relies on microfluidics.

  2. A Perfect Pair? Combining Keytruda And mRNA Therapy To Optimize Bladder Cancer Outcomes 8/7/2024

    AdventHealth's Guru Sonpavde, MD credits the patient-centric trial design, the city’s diversity, and the staff’s expertise with executing the trial for giving bladder cancer patients a chance at a quicker and fuller recovery. 

  3. Rising Allure And Critical Considerations Of Point-Of-Care Processing 8/1/2024

    Mobile and standard cleanroom infrastructures are becoming more popular to meet the logistical demands of personalized medicine and public health emergencies.

  4. Bridge RNAs: Principles, Applications, And Challenges 8/1/2024

    Bridge RNAs are structured noncoding RNAs that facilitate programmable recombination between target and donor DNA, enabling precise genomic rearrangements. A significant advantage is their modularity.

  5. In Vivo Genetic Medicines Need a Guide: The Answer Lies in Harnessing the Transcriptome 7/15/2024

    This article by Radar Therapeutics explains why the DNA/RNA revolution is underway and why solving specific targeting is next.

  6. End-To-End mRNA DS And DP Manufacturing Processes 7/10/2024

    This article demystifies the manufacture of mRNA encapsulated in lipid nanoparticles across unit operations for plasmid linearization, drug substance (DS) manufacture, and drug product (DP) manufacture.

  7. Innovation Advances In mRNA Medicine 7/9/2024

    The post-pandemic mRNA pipeline surge has led to a substantial investment in innovation. Let’s look at nonamplifying mRNA, saRNA, and circRNA.

  8. Making Cancer Vaccines Is Complex; New Platform Guidance Could Help 7/3/2024

    FDA's draft guidance on platforms is mostly for established, well-characterized modalities, but it also has implications for the emerging area of personalized medicine.

  9. CRISPR-Cas Genome Editing For Rejuvenation Of Aging Stem Cells 7/1/2024

    As stem cells age, their regenerative capacity declines due to accumulated genetic and epigenetic changes. Using CRISPR-Cas, scientists can directly edit these changes or modulate aging-related pathways.

  10. What Does FDA's Draft Platform Guidance Mean For CGT Companies? 6/17/2024

    Details of the FDA's highly-anticipated platform technology program were released in the form of a draft guidance. Let's explore with a former FDA/CBER regulator.